NCT02612311 2024-12-13
UNITY-CLL
TG Therapeutics, Inc.
Phase 3 Terminated
Clinical Trials
7 trialsNCT02742090 2024-07-03
Evaluate the Efficacy and Safety of TGR-1202 in Participants With Chronic Lymphocytic Leukemia Who Are Intolerant to Prior Therapy
TG Therapeutics, Inc.
Phase 2 Terminated
NCT03801525 2024-04-19
ULTRA-V
TG Therapeutics, Inc.
Phase 2/3 Terminated
NCT03828448 2023-07-24
Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïve Follicular Lymphoma
TG Therapeutics, Inc.
Phase 2 Terminated
NCT04016805 2023-07-24
Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax
TG Therapeutics, Inc.
Phase 2 Terminated
NCT03364231 2023-06-23
Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent Non-Hodgkin's Lymphoma
TG Therapeutics, Inc.
Phase 2 Completed
NCT02656303 2023-06-22
A Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With Umbralisib for Participants Previously Enrolled in Protocol UTX-TGR-304
TG Therapeutics, Inc.
Phase 2 Terminated